Stealth nanoparticles lower drug-resistant tumors' defenses

Date:

October 23, 2013

Source:

American Chemical Society

Summary:

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

Share:

Total shares:

FULL STORY

A layered nanoparticle with an anticancer drug core, a gene-silencing inner layer and a tumor-targeting outer layer could provide a new way to attack drug-resistant cancer cells.

Credit: American Chemical Society

A layered nanoparticle with an anticancer drug core, a gene-silencing inner layer and a tumor-targeting outer layer could provide a new way to attack drug-resistant cancer cells.

Credit: American Chemical Society

Some of the most dangerous cancers are those that can outmaneuver the very drugs designed to defeat them, but researchers are now reporting a new Trojan-horse approach. In a preliminary study in the journal ACS Nano focusing on a type of breast cancer that is highly resistant to current therapies, they describe a way to sneak small particles into tumor cells, lower their defenses and attack them with drugs, potentially making the therapy much more effective.

Paula T. Hammond and colleagues at the Koch Institute of Integrative Cancer Research at MIT note that triple-negative breast cancer (TNBC) is an aggressive disease that is difficult to treat with standard-of-care therapy, and patients' prognoses are poor. These cancer cells evade treatment by ramping up the production of certain proteins that protect tumors from chemotherapy drugs. Interfering with this process could give anticancer drugs a better chance at killing resistant tumors. Recent research into molecules called small interfering RNAs, or siRNAs, is opening doors into possible new treatments using this approach. These molecules can halt the production of particular proteins, so they are ideal candidates for dialing down the levels of protective proteins in tumors. But there are challenges to using siRNAs as part of a cancer therapy, so Hammond's team set out to address them with novel molecular engineering approaches.

They designed a two-stage, "stealth" drug delivery system to attack TNBC cells in mice, often used as stand-ins for humans in research. They created "layer-by-layer" nanoparticles through assembly of components in a certain order around a nano-sized core. An anticancer drug is loaded into the core of the particle, which is then wrapped in a layer of negatively charged siRNA, alternating with positively charged polypeptides, then coated on the outside with a stealthy tumor-targeting shell layer. That layer helps keep the particles in the body long enough for therapy to work. It also allows the particles to specifically bind to TNBC tumor cells. When tested in mice, the nanoparticles targeted the tumors and reduced the levels of protective proteins by nearly 80 percent. With the cancer cells rendered vulnerable, the nanoparticles' anticancer drug payload showed significantly enhanced therapeutic effects and shrunk tumors by 8-fold. The scientists state, "In summary, the results here provide a potential strategy to treat an aggressive and recurrent form of TNBC, as well as a means of adapting this platform to a broad range of controlled multi-drug therapies customizable to the cancer type in a singular nanoparticle delivery system." They also say that the "layer-by-layer" nanoparticle components are biocompatible and biodegradable, which will allow rapid translation into potential clinical benefits.

July 31, 2015  School is just around the corner, which means backpacks and packed lunches await your children. One expert offers tips for parents to promote healthy dental habits while away from ... read more

July 29, 2015  By blocking the expression of a certain gene in patients, researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their ... read more

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

June 10, 2015  Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional ... read more

May 8, 2014  Nanoparticles that stagger delivery of two drugs knock out aggressive tumors, new research shows. In studies with mice, the research team showed that this one-two punch, which relies on a ... read more

Apr. 20, 2014  Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers have discovered a biomarker called CD61 on the surface of ... read more